Display options
Cite
Ricard-Blum S, Vallet SD. Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells. Front Pharmacol. 2016;7:11doi: 10.3389/fphar.2016.00011.
Ricard-Blum, S., & Vallet, S. D. (2016). Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells. Frontiers in pharmacology, 711. https://doi.org/10.3389/fphar.2016.00011
Ricard-Blum, Sylvie, and Vallet, Sylvain D. "Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells." Frontiers in pharmacology vol. 7 (2016): 11. doi: https://doi.org/10.3389/fphar.2016.00011
Ricard-Blum S, Vallet SD. Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells. Front Pharmacol. 2016 Feb 04;7:11. doi: 10.3389/fphar.2016.00011. eCollection 2016. PMID: 26869928; PMCID: PMC4740388.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Feb 04;7:11. doi: 10.3389/fphar.2016.00011. eCollection 2016.

Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells.

Frontiers in pharmacology

Sylvie Ricard-Blum, Sylvain D Vallet

Affiliations

  1. University Claude Bernard Lyon 1, UMR 5246 Centre National de la Recherche Scientifique - University Lyon 1 - Institut National des Sciences Appliquées de Lyon - École Supérieure de Chimie Physique Électronique de Lyon Villeurbanne, France.

PMID: 26869928 PMCID: PMC4740388 DOI: 10.3389/fphar.2016.00011

Abstract

The extracellular matrix (ECM) is a source of bioactive fragments called matricryptins or matrikines resulting from the proteolytic cleavage of extracellular proteins (e.g., collagens, elastin, and laminins) and proteoglycans (e.g., perlecan). Matrix metalloproteinases (MMPs), cathepsins, and bone-morphogenetic protein-1 release fragments, which regulate physiopathological processes including tumor growth, metastasis, and angiogenesis, a pre-requisite for tumor growth. A number of matricryptins, and/or synthetic peptides derived from them, are currently investigated as potential anti-cancer drugs both in vitro and in animal models. Modifications aiming at improving their efficiency and their delivery to their target cells are studied. However, their use as drugs is not straightforward. The biological activities of these fragments are mediated by several receptor families. Several matricryptins may bind to the same matricellular receptor, and a single matricryptin may bind to two different receptors belonging or not to the same family such as integrins and growth factor receptors. Furthermore, some matricryptins interact with each other, integrins and growth factor receptors crosstalk and a signaling pathway may be regulated by several matricryptins. This forms an intricate 3D interaction network at the surface of tumor and endothelial cells, which is tightly associated with other cell-surface associated molecules such as heparan sulfate, caveolin, and nucleolin. Deciphering the molecular mechanisms underlying the behavior of this network is required in order to optimize the development of matricryptins as anti-cancer agents.

Keywords: anticancer drugs; endostatin; interaction networks; matricellular receptors; matricryptins

References

  1. J Biol Chem. 2000 Mar 17;275(11):8051-61 - PubMed
  2. Am J Pathol. 2000 May;156(5):1489-98 - PubMed
  3. J Biol Chem. 2000 Aug 4;275(31):23745-50 - PubMed
  4. J Biol Chem. 2000 Oct 20;275(42):32999-3007 - PubMed
  5. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1024-9 - PubMed
  6. J Biol Chem. 2001 Apr 20;276(16):13483-9 - PubMed
  7. Mol Cell. 2001 Apr;7(4):811-22 - PubMed
  8. J Cell Biol. 2001 Jul 23;154(2):459-68 - PubMed
  9. FEBS Lett. 2001 Aug 10;503(1):75-9 - PubMed
  10. BMC Cell Biol. 2001;2:18 - PubMed
  11. Cancer Res. 2001 Dec 15;61(24):8730-6 - PubMed
  12. Science. 2002 Jan 4;295(5552):140-3 - PubMed
  13. J Biol Chem. 2002 May 10;277(19):16464-9 - PubMed
  14. J Biol Chem. 2002 Aug 2;277(31):27872-9 - PubMed
  15. Cancer Res. 2002 Oct 1;62(19):5580-9 - PubMed
  16. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4766-71 - PubMed
  17. J Cell Biol. 2003 Apr 14;161(1):197-209 - PubMed
  18. J Biol Chem. 2003 Sep 26;278(39):37895-901 - PubMed
  19. J Biol Chem. 2004 Jan 23;279(4):2927-36 - PubMed
  20. J Biol Chem. 2004 Jan 23;279(4):2772-80 - PubMed
  21. Clin Cancer Res. 2003 Nov 1;9(14):5358-69 - PubMed
  22. J Biol Chem. 2004 Apr 23;279(17):17079-84 - PubMed
  23. J Cell Sci. 2005 Jan 15;118(Pt 2):343-56 - PubMed
  24. Science. 2005 Jan 7;307(5706):58-62 - PubMed
  25. Mol Pharmacol. 2005 Apr;67(4):1315-24 - PubMed
  26. Cancer Res. 2005 Jan 1;65(1):148-56 - PubMed
  27. Cancer Res. 2005 May 15;65(10):4353-61 - PubMed
  28. Matrix Biol. 2005 Sep;24(6):418-27 - PubMed
  29. J Clin Invest. 2005 Oct;115(10):2801-10 - PubMed
  30. Cancer Res. 2005 Dec 1;65(23):11044-50 - PubMed
  31. J Biol Chem. 2006 Jul 28;281(30):20932-9 - PubMed
  32. Bioconjug Chem. 2006 Jul-Aug;17(4):995-9 - PubMed
  33. Science. 2006 Aug 18;313(5789):968-71 - PubMed
  34. Sci STKE. 2006 Sep 26;2006(354):pe35 - PubMed
  35. IUBMB Life. 2006 Nov;58(11):647-53 - PubMed
  36. Cancer Res. 2006 Dec 1;66(23):11331-40 - PubMed
  37. Cancer Res. 2007 Feb 1;67(3):1105-12 - PubMed
  38. J Biol Chem. 2007 Apr 27;282(17):12484-91 - PubMed
  39. J Pept Sci. 2007 Apr;13(4):263-8 - PubMed
  40. Cancer Biol Ther. 2007 May;6(5):648-53 - PubMed
  41. Oncogene. 2007 Sep 27;26(44):6361-71 - PubMed
  42. Blood. 2007 Oct 15;110(8):2899-906 - PubMed
  43. Nat Rev Mol Cell Biol. 2007 Dec;8(12):957-69 - PubMed
  44. Int J Cancer. 2008 May 1;122(9):1972-80 - PubMed
  45. Crit Rev Ther Drug Carrier Syst. 2007;24(5):445-92 - PubMed
  46. Clin Cancer Res. 2008 Mar 1;14(5):1487-93 - PubMed
  47. Clin Cancer Res. 2008 Mar 1;14(5):1529-39 - PubMed
  48. Cancer Res. 2008 Apr 15;68(8):2885-94 - PubMed
  49. Genome Biol. 2008;9(5):224 - PubMed
  50. Clin Invest Med. 2008;31(3):E106-16 - PubMed
  51. Biochem Biophys Res Commun. 2008 Oct 24;375(3):287-91 - PubMed
  52. Int J Cancer. 2009 Jan 15;124(2):306-15 - PubMed
  53. J Exp Clin Cancer Res. 2008 Nov 04;27:61 - PubMed
  54. Nat Rev Cancer. 2009 Jan;9(1):57-63 - PubMed
  55. Mol Cancer Res. 2009 Feb;7(2):255-65 - PubMed
  56. J Nephrol. 2009 Jan-Feb;22(1):130-6 - PubMed
  57. J Cell Mol Med. 2009 Sep;13(9B):3687-98 - PubMed
  58. Cancer Sci. 2009 Aug;100(8):1510-9 - PubMed
  59. J Biol Chem. 2009 Aug 14;284(33):22029-40 - PubMed
  60. Biotechnol Appl Biochem. 2009 Aug 17;54(2):113-20 - PubMed
  61. J Biol Chem. 2009 Aug 14;284(33):22041-7 - PubMed
  62. Cell Tissue Res. 2010 Jan;339(1):269-80 - PubMed
  63. Int J Oncol. 2009 Oct;35(4):761-73 - PubMed
  64. Biochim Biophys Acta. 2010 Mar;1804(3):567-80 - PubMed
  65. Chin Med J (Engl). 2009 Aug 20;122(16):1947-51 - PubMed
  66. Blood. 2009 Nov 26;114(23):4897-906 - PubMed
  67. J Cell Commun Signal. 2009 Dec;3(3-4):311-22 - PubMed
  68. Clin Cancer Res. 2009 Dec 15;15(24):7462-7468 - PubMed
  69. Int J Biol Macromol. 2010 Apr 1;46(3):331-6 - PubMed
  70. FEBS J. 2010 Apr;277(8):1939-56 - PubMed
  71. J Biol Chem. 2010 Jul 2;285(27):20806-17 - PubMed
  72. Cancer Biother Radiopharm. 2008 Dec;23(6):735-40 - PubMed
  73. J Gastroenterol Hepatol. 2010 May;25(5):935-41 - PubMed
  74. FEBS J. 2010 Oct;277(19):3876-89 - PubMed
  75. Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90 - PubMed
  76. Int J Nanomedicine. 2010 Nov 24;5:1039-48 - PubMed
  77. Front Biosci (Landmark Ed). 2011 Jan 01;16:674-97 - PubMed
  78. Int J Cancer. 2011 Aug 1;129(3):751-61 - PubMed
  79. Mol Cancer Ther. 2011 Apr;10(4):603-14 - PubMed
  80. Curr Pharm Biotechnol. 2011 Aug;12(8):1101-16 - PubMed
  81. J Biol Chem. 2011 Jul 22;286(29):25947-62 - PubMed
  82. Bone. 2011 Oct;49(4):644-52 - PubMed
  83. J Clin Invest. 2011 Aug;121(8):3005-23 - PubMed
  84. Dose Response. 2011;9(3):369-76 - PubMed
  85. Cytoskeleton (Hoboken). 2011 Dec;68(12):671-93 - PubMed
  86. Br J Pharmacol. 2012 Jun;166(4):1247-60 - PubMed
  87. Pharmaceuticals (Basel). 2011 Dec;4(12):1551-1577 - PubMed
  88. Theranostics. 2012;2(1):66-75 - PubMed
  89. J Biol Chem. 2012 Apr 6;287(15):12204-16 - PubMed
  90. Clin Exp Metastasis. 2012 Jun;29(5):511-22 - PubMed
  91. J Neuroimmunol. 2012 May 15;246(1-2):1-9 - PubMed
  92. Protein Pept Lett. 2012 Sep;19(9):969-74 - PubMed
  93. PLoS One. 2012;7(4):e29587 - PubMed
  94. Sci Transl Med. 2012 May 30;4(136):136ra71 - PubMed
  95. Angiogenesis. 2012 Dec;15(4):697-711 - PubMed
  96. J Biol Chem. 2012 Aug 10;287(33):27601-13 - PubMed
  97. Curr Opin Struct Biol. 2012 Oct;22(5):583-90 - PubMed
  98. Physiology (Bethesda). 2012 Aug;27(4):213-22 - PubMed
  99. Cell Rep. 2012 Aug 30;2(2):223-30 - PubMed
  100. World J Surg Oncol. 2012 Aug 24;10:170 - PubMed
  101. Front Immunol. 2012 Aug 24;3:263 - PubMed
  102. J Biol Chem. 2012 Dec 21;287(52):43543-56 - PubMed
  103. J Biol Chem. 2012 Dec 14;287(51):43094-107 - PubMed
  104. Biomed Pharmacother. 2012 Dec;66(8):648-54 - PubMed
  105. J Biol Chem. 2013 Jan 11;288(2):1317-28 - PubMed
  106. PLoS One. 2012;7(12):e51044 - PubMed
  107. Cell Adh Migr. 2013 Jan-Feb;7(1):150-256 - PubMed
  108. Crit Rev Eukaryot Gene Expr. 2012;22(4):309-24 - PubMed
  109. FEBS J. 2013 May;280(10):2271-84 - PubMed
  110. Int J Biochem Cell Biol. 2013 May;45(5):1012-5 - PubMed
  111. Biochem Biophys Res Commun. 2013 Mar 22;432(4):549-52 - PubMed
  112. Nanoscale Res Lett. 2013 Apr 09;8(1):161 - PubMed
  113. Anticancer Drugs. 2013 Aug;24(7):677-89 - PubMed
  114. Respir Res. 2013 May 20;14(1):56 - PubMed
  115. J Clin Invest. 2013 Aug;123(8):3190-200 - PubMed
  116. Biochem J. 2014 Jan 1;457(1):137-49 - PubMed
  117. PLoS One. 2013 Dec 04;8(12):e80555 - PubMed
  118. Biochim Biophys Acta. 2014 Aug;1840(8):2589-98 - PubMed
  119. Front Oncol. 2014 Feb 03;4:4 - PubMed
  120. Med Oncol. 2014 Apr;31(4):930 - PubMed
  121. PLoS One. 2014 Mar 25;9(3):e92857 - PubMed
  122. Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a020768 - PubMed
  123. J Biol Chem. 2014 Jun 6;289(23):16114-28 - PubMed
  124. J Biol Chem. 2014 May 30;289(22):15340-9 - PubMed
  125. J Nanosci Nanotechnol. 2014 Jul;14(7):5075-87 - PubMed
  126. Gastroenterol Rep (Oxf). 2014 Feb;2(1):44-53 - PubMed
  127. Exp Dermatol. 2014 Jul;23(7):457-63 - PubMed
  128. FASEB J. 2014 Sep;28(9):3823-31 - PubMed
  129. Br J Cancer. 2014 Jul 8;111(1):139-48 - PubMed
  130. Regul Toxicol Pharmacol. 2014 Aug;69(3):512-23 - PubMed
  131. Appl Microbiol Biotechnol. 2014 Sep;98(18):7923-33 - PubMed
  132. Mol Clin Oncol. 2014 Jul;2(4):586-590 - PubMed
  133. Anticancer Drugs. 2014 Oct;25(9):1044-51 - PubMed
  134. J Cell Sci. 2014 Sep 1;127(Pt 17):3805-16 - PubMed
  135. Cell Death Dis. 2014 Aug 14;5:e1371 - PubMed
  136. Biomed Res Int. 2014;2014:103923 - PubMed
  137. Mol Carcinog. 2015 Nov;54(11):1340-53 - PubMed
  138. J Cancer Sci Ther. 2013 Jul 4;5(12):417-426 - PubMed
  139. Biochem Soc Trans. 2014 Dec;42(6):1643-6 - PubMed
  140. J Alzheimers Dis. 2015;44(4):1253-61 - PubMed
  141. Oncol Rep. 2015 Feb;33(2):675-84 - PubMed
  142. Int J Exp Pathol. 2015 Feb;96(1):1-10 - PubMed
  143. Matrix Biol. 2015 May-Jul;44-46:122-9 - PubMed
  144. J Thorac Oncol. 2015 Jan;10(1):206-11 - PubMed
  145. Biochim Biophys Acta. 2015 Jun;1850(6):1140-9 - PubMed
  146. Matrix Biol. 2015 Mar;42:11-55 - PubMed
  147. Protein Pept Lett. 2015;22(5):470-9 - PubMed
  148. Oncotarget. 2015 Mar 30;6(9):7182-94 - PubMed
  149. Mol Cancer Ther. 2015 May;14(5):1192-201 - PubMed
  150. Trends Cell Biol. 2015 Jul;25(7):388-97 - PubMed
  151. Biochimie. 2015 Jun;113:78-85 - PubMed
  152. Oncol Rep. 2015 Jun;33(6):2981-91 - PubMed
  153. Mol Med Rep. 2015 Aug;12(2):2068-74 - PubMed
  154. Front Immunol. 2015 Apr 14;6:169 - PubMed
  155. Int J Ophthalmol. 2015 Apr 18;8(2):234-8 - PubMed
  156. Front Immunol. 2015 Apr 21;6:182 - PubMed
  157. Technol Cancer Res Treat. 2016 Jun;15(3):498-508 - PubMed
  158. Front Immunol. 2015 May 06;6:201 - PubMed
  159. Front Immunol. 2015 May 15;6:231 - PubMed
  160. Onco Targets Ther. 2015 Jun 15;8:1483-91 - PubMed
  161. Exp Cell Res. 2015 Aug 1;336(1):130-40 - PubMed
  162. Hum Mol Genet. 2015 Oct 15;24(R1):R60-6 - PubMed
  163. Sci Adv. 2015;1(3):null - PubMed
  164. Mol Oncol. 2016 Jan;10(1):1-23 - PubMed
  165. Int J Clin Exp Med. 2015 Jun 15;8(6):8369-76 - PubMed
  166. Int J Clin Exp Med. 2015 Jun 15;8(6):8758-66 - PubMed
  167. Int Immunopharmacol. 2015 Oct;28(2):1102-5 - PubMed
  168. Protein Pept Lett. 2015;22(11):1025-30 - PubMed
  169. Biochim Biophys Acta. 2015 Dec;1850(12):2422-38 - PubMed
  170. Biochimie. 2016 Mar;122:300-13 - PubMed
  171. Am J Transl Res. 2015 Aug 15;7(8):1332-44 - PubMed
  172. Sci Rep. 2015 Sep 28;5:14503 - PubMed
  173. Int J Cell Biol. 2015;2015:563818 - PubMed
  174. Biomed Res Int. 2015;2015:453801 - PubMed
  175. Thorac Cancer. 2012 Aug;3(3):229-238 - PubMed
  176. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  177. J Biol Chem. 1994 Aug 19;269(33):20982-6 - PubMed
  178. Cancer Res. 1993 Jun 1;53(11):2661-6 - PubMed
  179. Cell. 1998 Feb 6;92(3):391-400 - PubMed
  180. Cancer Res. 1999 Jan 1;59(1):219-26 - PubMed

Publication Types